Cinclus Pharma Holding Valuation Multiples

Cinclus Pharma Holding Overview

About Cinclus Pharma Holding

Cinclus Pharma Holding AB is a clinical stage pharmaceutical company developing a drug for the treatment of erosive gastroesophageal reflux diseases, and a dual therapy treatment with an antibiotic targeting Helicobacter pylori which is a bacteria that occurs in the gastric and duodenal mucosa. The Company’s main target population is patients suffering from severe eGERD, where there is a lack of satisfactory treatment options.

Founded

2017

HQ

Employees

13

Website

cincluspharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $5M

EBITDA: ($28M)

EV

$35M

Valuation Multiples

Multiples.vc

Start free trial

Cinclus Pharma Holding Financials

Cinclus Pharma Holding reported last 12-month revenue of $5M and negative EBITDA of ($28M).

In the same LTM period, Cinclus Pharma Holding generated ($28M) in EBITDA losses and had net loss of ($25M).

Cinclus Pharma Holding P&L

In the most recent fiscal year, Cinclus Pharma Holding reported revenue of $6M and EBITDA of ($20M).

Cinclus Pharma Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX

Cinclus Pharma Holding Stock Performance

Cinclus Pharma Holding has current market cap of $87M, and enterprise value of $35M.

Cinclus Pharma Holding's stock price is $1.88.

Cinclus Pharma Holding Valuation Multiples

Cinclus Pharma Holding trades at 7.0x EV/Revenue multiple, and (1.3x) EV/EBITDA.

Cinclus Pharma Holding Financial Valuation Multiples

As of April 18, 2026, Cinclus Pharma Holding has market cap of $87M and EV of $35M.

Equity research analysts estimate Cinclus Pharma Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Cinclus Pharma Holding has a P/E ratio of (3.5x).

Cinclus Pharma Holding Margins & Growth Rates

Cinclus Pharma Holding's revenue in the last 12 month grew by 45%.

Cinclus Pharma Holding's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $2.1M for the same period.

Cinclus Pharma Holding's rule of 40 is (432%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cinclus Pharma Holding's rule of X is (417%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Cinclus Pharma Holding Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Cinclus Pharma Holding M&A Activity

Cinclus Pharma Holding acquired XXX companies to date.

Last acquisition by Cinclus Pharma Holding was on XXXXXXXX, XXXXX. Cinclus Pharma Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Cinclus Pharma Holding Investment Activity

Cinclus Pharma Holding invested in XXX companies to date.

Cinclus Pharma Holding made its latest investment on XXXXXXXX, XXXXX. Cinclus Pharma Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).